{"id":"NCT00965341","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients","officialTitle":"A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2009-08-25","resultsPosted":"2016-09-13","lastUpdate":"2016-09-13"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Cancer"],"interventions":[{"type":"DRUG","name":"Testosterone","otherNames":["Androderm","AndroGel","Delatestryl","Depo-Testosterone","Testosterone enanthate","Testosterone cypionate"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Testosterone","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical research study is to learn if and how testosterone replacement therapy may affect fatigue in males with advanced cancer and low testosterone levels.","primaryOutcome":{"measure":"Functional Assessment of Cancer Therapy-Fatigue Subscale (FACIT-F) at Day 29 (+/- 3 Days)","timeFrame":"Day 29 (+/- 3 days)","effectByArm":[{"arm":"Testosterone","deltaMin":12,"sd":13.8},{"arm":"Placebo","deltaMin":13,"sd":19.3}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":19},"commonTop":["Fatigue","Anorexia","Pain (NOS)","Dyspnea","Neuropathy: Sensory"]}}